Yes, corrective short-acting insulin is needed for steroid-induced hyperglycemia in diabetic patients.
A diabetic patient whose blood glucose rises after a cortisone injection should receive corrective insulin as part of a scheduled insulin regimen, not as standalone sliding-scale therapy. The most recent guidelines emphasize that correction insulin should be integrated with basal insulin or a basal-bolus regimen, particularly for glucocorticoid-induced hyperglycemia 1, 2.
Understanding Steroid-Induced Hyperglycemia
Glucocorticoids like cortisone cause a characteristic pattern of hyperglycemia:
- Peak effect occurs 4-6 hours after administration with disproportionate daytime hyperglycemia 1
- Blood glucose often normalizes overnight regardless of treatment 1
- The hyperglycemic effect matches the pharmacologic duration of the steroid used 1
This predictable pattern requires proactive insulin management rather than reactive correction alone.
Recommended Insulin Approach
For Short-Acting Steroids (like prednisone given once daily):
The standard approach is NPH insulin given concomitantly with the steroid dose, typically in the morning 1, 3. Because NPH peaks at 4-6 hours—matching the steroid's hyperglycemic effect—it provides superior coverage compared to long-acting basal insulins alone 1.
Correction insulin with rapid-acting analogs (aspart, lispro, glulisine) should be added before meals and at bedtime to address breakthrough hyperglycemia 4, 2. This correction insulin is customized to the patient's insulin sensitivity, not a rigid sliding scale 4.
Specific Dosing Guidance:
For patients already on diabetes medications:
- Add NPH insulin at 0.1-0.3 units/kg given with the steroid dose 5
- Increase correction insulin doses, sometimes requiring "extraordinary amounts" for higher steroid doses 1, 3
- Continue basal insulin if already prescribed, but adjust doses based on glucose monitoring 1
For insulin-naive patients with new steroid-induced hyperglycemia:
- Start basal-bolus insulin at 0.5-0.6 units/kg total daily dose if blood glucose is significantly elevated 5
- Add NPH at 0.1-0.4 units/kg matched to steroid timing 5
- Distribute as 40% basal and 60% prandial with correction doses 5
Critical Pitfalls to Avoid
Do not use sliding-scale insulin (SSI) alone—this reactive approach is strongly discouraged and leads to inadequate glycemic control 4, 2, 6. The 2012 Endocrine Society guideline explicitly recommends against prolonged SSI as the sole method for glycemic control 4.
Do not forget to adjust insulin as steroids taper—this is where many patients experience hypoglycemia 7, 8. Insulin doses must be reduced proportionally as glucocorticoid doses decrease. "Glucovigilance" during steroid tapering is essential 7.
Do not assume oral medications alone will suffice—while oral agents can be continued if fasting glucose is below 200 mg/dL (11.1 mmol/L), insulin is typically required for adequate control during steroid therapy 9, 10. For severe hyperglycemia or prolonged steroid courses, insulin is the recommended treatment 9.
Monitoring Requirements
- Check blood glucose before meals and at bedtime (minimum 4 times daily) 2
- Adjust insulin doses daily based on point-of-care glucose results 1, 3
- Anticipate changes in steroid dosing and proactively modify insulin regimens 1, 3
Evidence Strength
The recommendation for correction insulin as part of scheduled therapy (not SSI alone) comes from strong guideline consensus 4, 1, 4, 2. The specific use of NPH for steroid-induced hyperglycemia is supported by both guidelines 1, 3 and clinical trial data showing improved glycemic control with NPH-based protocols 11. A 2018 randomized trial demonstrated that an NPH insulin protocol significantly lowered mean blood glucose (226 vs. 269 mg/dL, p<0.0001) compared to usual care in hospitalized patients receiving corticosteroids 11.
The key principle: treat steroid-induced hyperglycemia proactively with scheduled insulin (preferably including NPH) plus correction doses, not reactively with sliding-scale insulin alone.